These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 28488218)

  • 21. ProSelection: A Novel Algorithm to Select Proper Protein Structure Subsets for in Silico Target Identification and Drug Discovery Research.
    Wang N; Wang L; Xie XQ
    J Chem Inf Model; 2017 Nov; 57(11):2686-2698. PubMed ID: 29016123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel resistance in cells with reduced beta-tubulin.
    Wang Y; Cabral F
    Biochim Biophys Acta; 2005 Jun; 1744(2):245-55. PubMed ID: 15950754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Theoretical and experimental study of polycyclic aromatic compounds as β-tubulin inhibitors.
    Olazarán FE; García-Pérez CA; Bandyopadhyay D; Balderas-Rentería I; Reyes-Figueroa AD; Henschke L; Rivera G
    J Mol Model; 2017 Mar; 23(3):85. PubMed ID: 28214932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insights into the interaction of discodermolide and docetaxel with tubulin. Mapping the binding sites of microtubule-stabilizing agents by using an integrated NMR and computational approach.
    Canales A; Rodríguez-Salarichs J; Trigili C; Nieto L; Coderch C; Andreu JM; Paterson I; Jiménez-Barbero J; Díaz JF
    ACS Chem Biol; 2011 Aug; 6(8):789-99. PubMed ID: 21539341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Similarity-based virtual screening for microtubule stabilizers reveals novel antimitotic scaffold.
    Ayoub AT; Klobukowski M; Tuszynski J
    J Mol Graph Model; 2013 Jul; 44():188-96. PubMed ID: 23871820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rotational-echo double-resonance NMR distance measurements for the tubulin-bound Paclitaxel conformation.
    Paik Y; Yang C; Metaferia B; Tang S; Bane S; Ravindra R; Shanker N; Alcaraz AA; Johnson SA; Schaefer J; O'Connor RD; Cegelski L; Snyder JP; Kingston DG
    J Am Chem Soc; 2007 Jan; 129(2):361-70. PubMed ID: 17212416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diaminothiazoles evade multidrug resistance in cancer cells and xenograft tumour models and develop transient specific resistance: understanding the basis of broad-spectrum versus specific resistance.
    Vasudevan S; Thomas SA; Sivakumar KC; Komalam RJ; Sreerekha KV; Rajasekharan KN; Sengupta S
    Carcinogenesis; 2015 Aug; 36(8):883-93. PubMed ID: 26014355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine.
    Pineda O; Farràs J; Maccari L; Manetti F; Botta M; Vilarrasa J
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4825-9. PubMed ID: 15341932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stabilization of microtubules by taxane diterpenoids: insight from docking and MD simulations.
    Yadava U; Gupta H; Roychoudhury M
    J Biol Phys; 2015 Mar; 41(2):117-33. PubMed ID: 25542396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogues as antitubulin agents.
    Penthala NR; Zong H; Ketkar A; Madadi NR; Janganati V; Eoff RL; Guzman ML; Crooks PA
    Eur J Med Chem; 2015 Mar; 92():212-20. PubMed ID: 25557492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of neolignans as microtubule stabilisers.
    Sathish Kumar B; Singh A; Kumar A; Singh J; Hasanain M; Singh A; Masood N; Yadav DK; Konwar R; Mitra K; Sarkar J; Luqman S; Pal A; Khan F; Chanda D; Negi AS
    Bioorg Med Chem; 2014 Feb; 22(4):1342-54. PubMed ID: 24457094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The bioactive Taxol conformation on beta-tubulin: experimental evidence from highly active constrained analogs.
    Ganesh T; Guza RC; Bane S; Ravindra R; Shanker N; Lakdawala AS; Snyder JP; Kingston DG
    Proc Natl Acad Sci U S A; 2004 Jul; 101(27):10006-11. PubMed ID: 15226503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.
    Tommasi S; Mangia A; Lacalamita R; Bellizzi A; Fedele V; Chiriatti A; Thomssen C; Kendzierski N; Latorre A; Lorusso V; Schittulli F; Zito F; Kavallaris M; Paradiso A
    Int J Cancer; 2007 May; 120(10):2078-85. PubMed ID: 17285590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
    Cai P; Lu P; Sharom FJ; Fang WS
    Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docking and molecular dynamics studies of the binding between Peloruside A and tubulin.
    Liao SY; Mo GQ; Chen JC; Zheng KC
    J Enzyme Inhib Med Chem; 2014 Oct; 29(5):702-9. PubMed ID: 24156744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations.
    Athar M; Lone MY; Khedkar VM; Radadiya A; Shah A; Jha PC
    Comb Chem High Throughput Screen; 2017; 20(8):682-695. PubMed ID: 28486912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
    Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E
    Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Function and structure-based screening of compounds, peptides and proteins to identify drug candidates.
    Malik V; Dhanjal JK; Kumari A; Radhakrishnan N; Singh K; Sundar D
    Methods; 2017 Dec; 131():10-21. PubMed ID: 28843611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
    Davis GD; Vasanthi AH
    Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
    Mozzetti S; Ferlini C; Concolino P; Filippetti F; Raspaglio G; Prislei S; Gallo D; Martinelli E; Ranelletti FO; Ferrandina G; Scambia G
    Clin Cancer Res; 2005 Jan; 11(1):298-305. PubMed ID: 15671559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.